Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the EU / 2025-523425-17-00
Authorised, recruiting Phase II

PODOMOUNT-Basket, a Phase II, multicentre, randomised, 2-arm parallel-group, double-blind, placebo-controlled basket trial to assess safety, tolerability, PK, and efficacy of BI 764198 in four proteinuric kidney diseases

2025-523425-17-00 · tracked via the Priya Life Science EU tracker
Sponsor
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A
Sponsor type
Pharmaceutical company, Pharmaceutical company
Therapeutic area
Nutritional and Metabolic Diseases
Decision date
19/05/2026
Enrollment target
66
Sites
Portugal, Greece, Italy, Poland, Estonia, Slovakia, Sweden, Denmark, Belgium, Norway, Romania, France, Spain, Germany, Netherlands, Croatia

Condition studied

Proteinuric kidney diseases

Investigational medicinal product(s)

BI 764198Placebo matching BI 764198

Eligibility

Age group
18-64 years, 0-17 years, 65+ years
Sex
Female, Male

Primary endpoint

Relative change from baseline to Week 20 in 24-hr UPCR (mg/g)

Endpoint detail

Treatment response, defined as at least 25% relative reduction in 24-hr UPCR from baseline to Week 20, Treatment response, defined as at least 40% relative reduction in 24-hr UPCR from baseline to Week 20, Absolute change in eGFR in mL/min/1.73m2 (based on cystatin C) from baseline to Week 20

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-523425-17-00 on CTIS ↗ ← All trials in the EU